CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2006-02-27): CORRECTION: Atorvastatin appears safe at high doses

Clinical

CORRECTION: Atorvastatin appears safe at high doses

Last Updated: 2006-02-27 7:53:40 -0400 (Reuters Health)

[Corrects story posted Feb 20, 2006. Amends dosage group in paragraph 6, changing "...three in the atorvastatin 20 mg group..." to "...three in the atorvastatin 10 mg group..."]

NEW YORK (Reuters Health) - A high dose of atorvastatin (80 mg) has a safety profile similar to that of a lower dose of the drug (10 mg), results of a meta-analysis show.

For patients at very high risk for coronary heart disease, the National Cholesterol Education Panel recommends aggressive lowering of low-density lipoprotein cholesterol. According to Dr. Connie Newman and colleagues at Pfizer Global Pharmaceuticals in New York, physicians may be concerned about prescribing statins at the doses required to meet these recommendations.

To assess the safety of the drug at the different doses, Dr. Newman's group pooled data from 49 clinical trials conducted between 1992 and 2004, which included data for 14,236 patients treated for an average of 2 weeks to 52 months. Treatment comprised atorvastatin 10 mg (n = 7258), atorvastatin 80 mg (n = 4798), or placebo (n = 2180).

Overall, the adverse event profiles for the three groups were similar, the authors report in the American Journal of Cardiology for January. There were actually more serious, nonfatal adverse events documented in the placebo group (134.5/1000 patient-years) than in either atorvastatin group (92.0/1000 in the 10 mg group and 82.2/1000 in the 80 mg group).

Rhabdomyolysis, a particular concern with statin treatment, was not observed in any of the patients.

Persistent elevations in alanine aminotransferase and aspartate aminotransferase > 3 times the upper limit of normal were documented in one patient in the placebo group, three in the atorvastatin 10 mg group, and two in the atorvastatin 80 mg group. Five patients receiving atorvastatin 80 developed hepatitis, which resolved within 4 weeks after discontinuing the drug.

The incidence of hematuria or albuminuria was low and similar in the two atorvastatin groups.

"The results of this analysis support the positive safety profile of atorvastatin at the highest dose," Dr. Newman and her colleagues conclude.

Am J Cardiol 2006;97:61-67.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.